BR112012017168A2 - sistema terapêutico transdérmico para administração de rivastigmina ou seus derivados - Google Patents

sistema terapêutico transdérmico para administração de rivastigmina ou seus derivados

Info

Publication number
BR112012017168A2
BR112012017168A2 BR112012017168-2A BR112012017168A BR112012017168A2 BR 112012017168 A2 BR112012017168 A2 BR 112012017168A2 BR 112012017168 A BR112012017168 A BR 112012017168A BR 112012017168 A2 BR112012017168 A2 BR 112012017168A2
Authority
BR
Brazil
Prior art keywords
rivastigmine
therapeutic system
transdermal therapeutic
administration
derivatives
Prior art date
Application number
BR112012017168-2A
Other languages
English (en)
Other versions
BR112012017168B1 (pt
Inventor
Hausner Heike
Schurad Bjorn
Original Assignee
Acino Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017168(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acino Ag filed Critical Acino Ag
Publication of BR112012017168A2 publication Critical patent/BR112012017168A2/pt
Publication of BR112012017168B1 publication Critical patent/BR112012017168B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
    • A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

sistema terapêutico transdérmico para administração de rivastigmina ou seus derivados. a presente invenção refere-se a um sistema terapêutico trandérmico para administração de uma substância ativa através da pele abrangendo: a) uma camada de cobertura, b) um reservatório localizado na camada de cobertura compreendendo uma matriz polimérica contendo a substância ativa, c) uma camada adesiva localizada no reservatório que compreende um adesivo de contato, d) uma camada removível localizada na camada adesiva, sendo que a substância ativa se trata de rivastigmina, cujo sal fisiologicamente compatível se trata de hidrato, solvato ou derivado, caracterizado pelo fato de que a matriz polimérica do reservatório não apresenta nem grupos hidroxila nem grupos carboxila.
BR112012017168-2A 2009-12-22 2010-12-14 Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero BR112012017168B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09180413 2009-12-22
EP09180413.8 2009-12-22
EP10154648.9 2010-02-25
EP10154648 2010-02-25
PCT/EP2010/069654 WO2011076621A2 (de) 2009-12-22 2010-12-14 Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten

Publications (2)

Publication Number Publication Date
BR112012017168A2 true BR112012017168A2 (pt) 2018-05-02
BR112012017168B1 BR112012017168B1 (pt) 2022-03-15

Family

ID=43383419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017168-2A BR112012017168B1 (pt) 2009-12-22 2010-12-14 Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero

Country Status (16)

Country Link
US (1) US8962014B2 (pt)
EP (1) EP2515886B1 (pt)
JP (1) JP6083734B2 (pt)
KR (1) KR101674240B1 (pt)
CN (1) CN102711744B (pt)
AU (1) AU2010335309B2 (pt)
BR (1) BR112012017168B1 (pt)
CA (1) CA2785117C (pt)
CY (1) CY1120283T1 (pt)
DK (1) DK2515886T3 (pt)
ES (1) ES2670227T3 (pt)
MX (1) MX350357B (pt)
NO (1) NO2515886T3 (pt)
PL (1) PL2515886T3 (pt)
PT (1) PT2515886T (pt)
WO (1) WO2011076621A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332772A1 (en) 2009-10-30 2018-06-13 IX Biopharma Ltd Fast dissolving solid dosage form
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
SI2468274T1 (sl) * 2010-12-14 2015-10-30 Acino Ag Transdermalni terapevtski sistem za dajanje aktivne snovi
JP6017543B2 (ja) * 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
JP6102739B2 (ja) * 2011-08-31 2017-03-29 東洋インキＳｃホールディングス株式会社 貼付剤
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
EP2821070B1 (en) 2012-02-28 2018-02-21 Nichiban Co. Ltd. Adhesive skin patch
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
CN103933018A (zh) * 2013-01-18 2014-07-23 江苏康倍得药业有限公司 一种透皮给药系统
US20180271800A1 (en) 2017-03-24 2018-09-27 E Ink California, Llc Microcell systems for delivering active molecules
US10308408B2 (en) 2014-05-15 2019-06-04 Nichiban Co., Ltd. Packaging for adhesive patch containing rivastigmine
CA2962059C (en) * 2014-09-23 2020-03-24 Equistar Chemicals, Lp Polyolefin-based compositions, adhesives, and related multi-layered structures prepared therefrom
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
DE102015119789A1 (de) * 2015-11-16 2017-05-18 Denso-Holding Gmbh & Co. Korrosionsschutzzusammensetzung umfassend Polyisobutylene
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
CN110446491A (zh) 2017-03-24 2019-11-12 伊英克加利福尼亚有限责任公司 调节活性物质给予速率的包含带电粒子或磁性粒子的微单元递送系统
TWI714347B (zh) 2017-11-14 2020-12-21 美商伊英克加利福尼亞有限責任公司 包含多孔導電電極層之電泳主動遞送系統
WO2019201755A1 (en) * 2018-04-17 2019-10-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of solifenacin
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US11938214B2 (en) 2019-11-27 2024-03-26 E Ink Corporation Benefit agent delivery system comprising microcells having an electrically eroding sealing layer
EP4236927A4 (en) 2020-10-29 2024-10-16 E Ink Corp MICROCELL SYSTEMS FOR DELIVERY OF HYDROPHILIC ACTIVE MOLECULES
EP4236926A4 (en) 2020-10-29 2024-08-28 E Ink Corp MICROCELL SYSTEMS FOR BENEFICIAL AGENT DELIVERY

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
JPS63307818A (ja) 1987-06-08 1988-12-15 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH07116025B2 (ja) 1988-03-11 1995-12-13 積水化学工業株式会社 貼付剤
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
JPH08193030A (ja) 1995-01-12 1996-07-30 Nitto Denko Corp エメダスチン貼付製剤
JPH10152434A (ja) 1996-09-26 1998-06-09 Nitto Denko Corp 経皮吸収型製剤
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
US20040258741A1 (en) * 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations
JP4478757B2 (ja) * 2002-04-19 2010-06-09 日東電工株式会社 ビソプロロール含有貼付剤
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) * 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
AU2006343077B2 (en) * 2006-05-08 2012-11-08 Teikoku Seiyaku Co., Ltd. Tansdermally absorbable preparation comprising anti-dementia agent
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
JP2009022730A (ja) * 2007-06-18 2009-02-05 Kyoritsu Yakuhin Kogyo Kk 貼付剤

Also Published As

Publication number Publication date
CN102711744A (zh) 2012-10-03
BR112012017168B1 (pt) 2022-03-15
PL2515886T3 (pl) 2018-08-31
WO2011076621A3 (de) 2012-02-09
US20130261571A1 (en) 2013-10-03
CY1120283T1 (el) 2019-07-10
EP2515886B1 (de) 2018-04-11
CA2785117A1 (en) 2011-06-30
US8962014B2 (en) 2015-02-24
EP2515886A2 (de) 2012-10-31
AU2010335309B2 (en) 2015-08-20
AU2010335309A1 (en) 2012-07-19
ES2670227T3 (es) 2018-05-29
JP2013515025A (ja) 2013-05-02
JP6083734B2 (ja) 2017-02-22
CA2785117C (en) 2016-12-06
KR101674240B1 (ko) 2016-11-08
CN102711744B (zh) 2014-06-25
MX2012007214A (es) 2012-09-12
PT2515886T (pt) 2018-05-23
NO2515886T3 (pt) 2018-09-08
KR20120128606A (ko) 2012-11-27
WO2011076621A2 (de) 2011-06-30
MX350357B (es) 2017-09-05
DK2515886T3 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
BR112012017168A2 (pt) sistema terapêutico transdérmico para administração de rivastigmina ou seus derivados
BRPI0719115B8 (pt) sistema terapêutico transdérmico para administração de buprenorfina à pele
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
BR112014005543A2 (pt) sistema de descarte de medicação geral
BR112013010342A8 (pt) módulo contendo medicamento e cânula da agulha
BR112015013660A2 (pt) sistema de entrega transdérmica
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
NZ711546A (en) Drug delivery devices with drug-permeable component and methods
BR112015005944A2 (pt) dispositivo de entrega de fármaco transdérmico
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
ECSP099635A (es) Formulaciones líquidas que forman una capa dérmica para la liberación de fármacos a la piel
UY32765A (es) Preparaciones insulinicas de accion lenta
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112013001299A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
BRPI0411032A (pt) composição adesiva hidrófila, artigo médico, método para a fabricação da composição adesiva, e, dispositivo de administração transdérmica
BR112014004635A2 (pt) sistema terapêutico transdérmico para cloridrato de ácido 5-aminolavulínico
NZ709521A (en) Transdermal dosage form for low-melting point active agent
Yang et al. Multiscale study on the enhancing effect and mechanism of borneolum on transdermal permeation of drugs with different log P values and molecular sizes
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
ES2525066T3 (es) Uso terapéutico de preparaciones farmacéuticas que contienen fármacos antitumorales unidos a ácido hialurónico en el tratamiento de neoplasias

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: LUYE PHARMA AG (DE)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/70 , A61K 31/27 , A61K 31/445 , A61K 31/55

Ipc: A61K 47/34 (2017.01), A61K 47/02 (2006.01), A61K 3

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.